ImmunoCellular Therapeutics (IMUC) Sees Large Volume Increase

Shares of ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) saw unusually-high trading volume on Tuesday . Approximately 5,130,167 shares traded hands during trading, an increase of 247% from the previous session’s volume of 1,479,029 shares.The stock last traded at $0.26 and had previously closed at $0.23.

The firm has a market capitalization of $5.23, a PE ratio of -0.08 and a beta of 0.77.

ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) last released its quarterly earnings data on Tuesday, November 21st. The biotechnology company reported ($0.40) EPS for the quarter.

COPYRIGHT VIOLATION NOTICE: “ImmunoCellular Therapeutics (IMUC) Sees Large Volume Increase” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.themarketsdaily.com/2018/02/15/immunocellular-therapeutics-imuc-sees-large-volume-increase.html.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply